SG11202012342WA - Constructs targeting prostate-specific membrane antigen (psma) and uses thereof - Google Patents

Constructs targeting prostate-specific membrane antigen (psma) and uses thereof

Info

Publication number: SG11202012342WA
Authority: SG; Singapore
Prior art keywords: psma; specific membrane; membrane antigen; constructs targeting; targeting prostate
Prior art date: 2018-06-18

Application number

SG11202012342WA

Inventor

Hong Liu

Hongruo Yun

Xiaomei Ge

Zhiyuan Yang

Lianxing Liu

Pengbo Zhang

Yixiang Xu

Shan Li

Lucas Horan

Original Assignee

Eureka Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-18

Filing date

2019-06-17

Publication date

2021-01-28

2019-06-17 Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc

2021-01-28 Publication of SG11202012342WA publication Critical patent/SG11202012342WA/en

Links

102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title 1
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title 1
230000008685 targeting Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4276—Prostate specific membrane antigen [PSMA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
General Physics & Mathematics (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)

SG11202012342WA 2018-06-18 2019-06-17 Constructs targeting prostate-specific membrane antigen (psma) and uses thereof SG11202012342WA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862686605P	2018-06-18	2018-06-18
PCT/US2019/037534 WO2019245991A1 (en)	2018-06-18	2019-06-17	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof

Publications (1)

Publication Number	Publication Date
SG11202012342WA true SG11202012342WA (en)	2021-01-28

Family

ID=68983831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202012342WA SG11202012342WA (en)	2018-06-18	2019-06-17	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof

Country Status (11)

Country	Link
US (2)	US11993661B2 (en)
EP (1)	EP3806904A4 (en)
JP (2)	JP7511308B2 (en)
CN (1)	CN112469440B (en)
AU (1)	AU2019288136A1 (en)
CA (1)	CA3103936A1 (en)
IL (1)	IL279373A (en)
PH (1)	PH12020552181A1 (en)
SG (1)	SG11202012342WA (en)
TW (1)	TWI853817B (en)
WO (1)	WO2019245991A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2767209C2 (en)	2015-10-23	2022-03-16	Еурека Терапьютикс, Инк.	Chimeric antibody/t-cell receptor structures and their applications
AU2018258045B2 (en)	2017-04-26	2024-02-29	Eureka Therapeutics, Inc.	Chimeric antibody/T-cell receptor constructs and uses thereof
SG11202012342WA (en)	2018-06-18	2021-01-28	Eureka Therapeutics Inc	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CA3104098A1 (en) *	2018-06-21	2019-12-26	Regeneron Pharmaceuticals, Inc.	Bispecific anti-psma x anti-cd28 antibodies and uses thereof
WO2021190583A1 (en) *	2020-03-25	2021-09-30	江苏恒瑞医药股份有限公司	Anti-psma antibody-exatecan analogue conjugate and medical use thereof
IL299748A (en)	2020-07-08	2023-03-01	Lava Therapeutics N V	Antibodies that bind psma and gamma-delta t cell receptors
US20230293687A1 (en) *	2020-07-29	2023-09-21	Eureka Therapeutics, Inc.	T cells and chimeric stimulating receptors and uses thereof
JP2023538891A (en)	2020-08-19	2023-09-12	ゼンコアインコーポレイテッド	Anti-CD28 composition
TW202309090A (en)	2021-05-05	2023-03-01	德商英麥提克生物技術股份有限公司	Improved bma031 antigen binding polypeptides
EP4482585A1 (en)	2022-02-23	2025-01-01	Xencor, Inc.	Anti-cd28 x anti-psma antibodies
WO2023215738A1 (en) *	2022-05-02	2023-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
WO2024186656A1 (en)	2023-03-03	2024-09-12	Arsenal Biosciences, Inc.	Systems targeting psma and ca9
WO2025096433A1 (en) *	2023-10-30	2025-05-08	Eureka Therapeutics, Inc.	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
WO2025093035A1 (en) *	2023-11-03	2025-05-08	Utc Therapeutics (Shanghai) Co., Ltd.	Cd40-targetting antibodies and uses thereof

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE108068T1 (en)	1987-09-23	1994-07-15	Bristol Myers Squibb Co	ANTIBODY HETEROCONJUGATES FOR KILLING HIV-INFECTED CELLS.
EP0420942A1 (en)	1988-06-24	1991-04-10	The Dow Chemical Company	Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
PT90959B (en)	1988-06-24	1995-05-04	Dow Chemical Co	PROCESS FOR THE PREPARATION OF BIFUNCTIONAL MACROCYCLIC CHELANTES, OF THEIR COMPLEXES AND THEIR CONJUGATES WITH ANTIBODIES
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE144793T1 (en)	1989-06-29	1996-11-15	Medarex Inc	BISPECIFIC REAGENTS FOR AIDS THERAPY
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
KR100272077B1 (en)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2113940T3 (en)	1990-12-03	1998-05-16	Genentech Inc	ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
JPH06507398A (en)	1991-05-14	1994-08-25	リプリジェン　コーポレーション	Heterogeneous conjugate antibody for treatment of HIV infection
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE207080T1 (en)	1991-11-25	2001-11-15	Enzon Inc	MULTIVALENT ANTIGEN-BINDING PROTEINS
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JPH08511420A (en)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	Body
GB9400415D0 (en)	1994-01-11	1994-03-09	Bp Chemicals Additives	Detergent compositions
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
DK2275119T3 (en)	1995-07-27	2013-11-11	Genentech Inc	Stable, isotonic lyophilized protein formulation
DE19544393A1 (en)	1995-11-15	1997-05-22	Hoechst Schering Agrevo Gmbh	Synergistic herbicidal mixtures
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6150508A (en)	1996-03-25	2000-11-21	Northwest Biotherapeutics, Inc.	Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DE69735294T2 (en)	1996-03-25	2006-09-21	Medarex Inc.	SPECIFIC MONOCLONAL ANTIBODIES FOR THE EXTRACELLULAR DOMAIN OF PROTASTA SPECIFIC MEMBRANE ANTIGEN
ES2190087T3 (en)	1997-06-13	2003-07-16	Genentech Inc	STABILIZED FORMULATION OF AN ANTIBODY.
WO1998058964A1 (en)	1997-06-24	1998-12-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
DE69840412D1 (en)	1997-10-31	2009-02-12	Genentech Inc	METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ES2292236T3 (en)	1998-04-02	2008-03-01	Genentech, Inc.	VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
EP1235842A4 (en)	1999-10-15	2003-04-23	Univ Massachusetts	GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
JP2003516755A (en)	1999-12-15	2003-05-20	ジェネンテック・インコーポレーテッド	Shotgun scanning, a combined method for mapping functional protein epitopes
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
HK1047770A1 (en)	2000-02-24	2003-03-07	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
AU2001275474A1 (en)	2000-06-12	2001-12-24	Akkadix Corporation	Materials and methods for the control of nematodes
EA013563B1 (en)	2000-10-06	2010-06-30	Киова Хакко Кирин Ко., Лтд.	A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2360169B1 (en) *	2001-10-23	2015-10-14	Psma Development Company, L.L.C.	PSMA antibodies
PL213948B1 (en)	2001-10-25	2013-05-31	Genentech Inc	Glycoprotein compositions
EP1461423B1 (en)	2001-12-03	2008-05-14	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
JPWO2003085119A1 (en)	2002-04-09	2005-08-11	協和醗酵工業株式会社	Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
PL373256A1 (en)	2002-04-09	2005-08-22	Kyowa Hakko Kogyo Co, Ltd.	Cells with modified genome
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	MEDICAMENT CONTAINING ANTIBODY COMPOSITION APPROPRIATE TO PATIENT SUFFERING FROM POLYMORPHISM FC gammma RIIIA
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
EP1391213A1 (en)	2002-08-21	2004-02-25	Boehringer Ingelheim International GmbH	Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en)	2002-12-16	2011-03-30	Genentech, Inc.	Immunoglobulin variants and uses thereof
EP1585767A2 (en)	2003-01-16	2005-10-19	Genentech, Inc.	Synthetic antibody phage libraries
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (en)	2003-11-05	2010-05-20	Roche Glycart Ag	FC RECEPTOR AND EFFECTOR FUNCTION
JPWO2005053742A1 (en)	2003-12-04	2007-06-28	協和醗酵工業株式会社	Medicament containing antibody composition
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PL1737891T3 (en)	2004-04-13	2013-08-30	Hoffmann La Roche	Anti-p-selectin antibodies
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
WO2006034488A2 (en)	2004-09-23	2006-03-30	Genentech, Inc.	Cysteine engineered antibodies and conjugates
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2577292T3 (en)	2005-11-07	2016-07-14	Genentech, Inc.	Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
JP2009536527A (en)	2006-05-09	2009-10-15	ジェネンテック・インコーポレーテッド	Binding polypeptide with optimized scaffold
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal display panel driving device and driving method thereof
JP2011505795A (en)	2007-11-27	2011-03-03	ヴィヴェンティアバイオテクノロジーズインコーポレーティッド	Antibody against cancer-associated epitope of variant NFKBIB and use thereof
PL2235064T3 (en)	2008-01-07	2016-06-30	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2738566C (en) *	2008-10-01	2024-04-30	Micromet Ag	Bispecific single chain antibodies with specificity for high molecular weight target antigens
MX346731B (en)	2010-04-23	2017-03-30	Genentech Inc *	Production of heteromultimeric proteins.
US20130280220A1 (en)	2012-04-20	2013-10-24	Nabil Ahmed	Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN112458057A (en)	2012-10-02	2021-03-09	纪念斯隆-凯特琳癌症中心	Compositions and methods for immunotherapy
WO2016054520A2 (en) *	2014-10-03	2016-04-07	The California Institute For Biomedical Research	Engineered cell surface proteins and uses thereof
GB201514875D0 (en)	2015-08-20	2015-10-07	Autolus Ltd	Receptor
RU2767209C2 (en)	2015-10-23	2022-03-16	Еурека Терапьютикс, Инк.	Chimeric antibody/t-cell receptor structures and their applications
EP3442567A4 (en)	2016-04-13	2019-12-18	Orimabs Ltd.	ANTI-PSMA ANTIBODIES AND THEIR USE
AU2018258045B2 (en)	2017-04-26	2024-02-29	Eureka Therapeutics, Inc.	Chimeric antibody/T-cell receptor constructs and uses thereof
SG11202012342WA (en)	2018-06-18	2021-01-28	Eureka Therapeutics Inc	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof

2019
- 2019-06-17 SG SG11202012342WA patent/SG11202012342WA/en unknown
- 2019-06-17 US US17/253,589 patent/US11993661B2/en active Active
- 2019-06-17 AU AU2019288136A patent/AU2019288136A1/en not_active Abandoned
- 2019-06-17 EP EP19822284.6A patent/EP3806904A4/en not_active Withdrawn
- 2019-06-17 CA CA3103936A patent/CA3103936A1/en not_active Abandoned
- 2019-06-17 JP JP2020570458A patent/JP7511308B2/en active Active
- 2019-06-17 WO PCT/US2019/037534 patent/WO2019245991A1/en not_active Ceased
- 2019-06-17 CN CN201980048331.3A patent/CN112469440B/en active Active
- 2019-06-18 TW TW108121155A patent/TWI853817B/en active
2020
- 2020-12-10 IL IL279373A patent/IL279373A/en unknown
- 2020-12-14 PH PH12020552181A patent/PH12020552181A1/en unknown
2024
- 2024-04-19 US US18/640,985 patent/US20250011463A1/en not_active Abandoned
- 2024-06-19 JP JP2024098587A patent/JP2024153614A/en active Pending

Also Published As

Publication number	Publication date
CN112469440B (en)	2024-09-06
JP7511308B2 (en)	2024-07-05
AU2019288136A1 (en)	2021-01-07
JP2021526844A (en)	2021-10-11
TW202015729A (en)	2020-05-01
WO2019245991A1 (en)	2019-12-26
US20250011463A1 (en)	2025-01-09
US11993661B2 (en)	2024-05-28
TWI853817B (en)	2024-09-01
EP3806904A1 (en)	2021-04-21
CA3103936A1 (en)	2019-12-26
PH12020552181A1 (en)	2021-06-28
CN112469440A (en)	2021-03-09
US20220185910A1 (en)	2022-06-16
IL279373A (en)	2021-01-31
EP3806904A4 (en)	2022-04-27
JP2024153614A (en)	2024-10-29

Publication	Publication Date	Title
IL279373A (en)	2021-01-31	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
PH12020551716A1 (en)	2021-07-26	Anti-ror antibody constructs
EP3807321A4 (en)	2022-03-02	ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
IL275547A (en)	2020-08-31	Antigen-binding proteins targeting shared antigens
IL288960A (en)	2022-02-01	Radiolabeled compounds targeting the prostate-specific membrane antigen
SG10201913579WA (en)	2020-02-27	Chimeric antibody/t-cell receptor constructs and uses thereof
EP3684124A4 (en)	2021-08-25	REFERENCE SIGNAL CONFIGURATION, SENDING AND RECEIVING PROCEDURES AND DEVICE
EP3601368A4 (en)	2021-03-31	Tumor antigen presentation inducer constructs and uses thereof
MX2017006094A (en)	2017-07-19	Anti-interleukin-33 antibodies and uses thereof.
EP3291836A4 (en)	2018-11-14	Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
IL276978A (en)	2020-10-29	Il-6 antibodies and fusion constructs and conjugates thereof
IL277542A (en)	2020-11-30	Constructs targeting cd22 and uses thereof
MX2018002106A (en)	2018-06-15	Therapeutic hpv18 vaccines.
DK3270965T3 (en)	2020-06-08	CD48 ANTIBODIES AND CONJUGATES THEREOF
EP3166959A4 (en)	2017-12-13	Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof
EP3595719A4 (en)	2020-12-30	Linker units and molecular constructs comprising same
IL297073B1 (en)	2023-08-01	Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
EP3096773A4 (en)	2018-02-21	Receptor targeting constructs and uses thereof
DK3331553T3 (en)	2022-08-01	PREVIOUSLY UNKNOWN ANTIHUMAN GPVI ANTIBODIES AND USES THEREOF
DK3668272T3 (en)	2022-01-31	HOLDER, HEATER AND PROCEDURE
IL289039A (en)	2022-02-01	Prostate specific membrane antigen (psma) ligands and uses thereof
IL265236A (en)	2019-05-30	Therapeutic multi-targeting constructs and uses thereof
IL286799A (en)	2021-10-31	Fusion constructs and uses thereof
HK40043308A (en)	2021-09-10	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
HK40015078A (en)	2020-08-28	Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens